

Index and Full Text search


Cortellis

There are different ways of searching in Cortellis: *Index* and *Full Text*. This guide explains how they work and when they should be utilized when searching drugs, companies, patents, deals, clinical trials, regulatory and other types of information.

The *Index* option searches fields with controlled vocabulary such as indication, mechanism of action or technology. These fields are designated by the editorial team, according to ontologies in Cortellis. This type of search is available for all report types in *Quick Search* (at the top of every page) and most fields in *Advanced Search*.

Index search is recommended to find results directly associated to your keyword, rather than making a reference to it, e.g. finding results on a specific drug -lacosamide- vs finding competitor drugs that mention lacosamide in their profile.

Example 1: *Index* search “lacosamide” retrieves 4 results corresponding to different formulations of this drug.



The screenshot shows the Cortellis search interface. The search term "lacosamide" is entered in the search bar, and the "Index" search type is selected. The results page shows 4 results found for the search term "lacosamide". The results are listed in a table with columns for Report Type, Results, Per page, and Sort by. The results are:

- Broker Research (4555)**: [lacosamide](#)
Highest Status: Launched
Last Change Date: 04-Apr-2021
In September 2014, a single loading dose administration option for all formulations of **lacosamide** was approved in the US [1726996], [1730656], [1889546].
- Companies (0)**: [lacosamide \(oral extended release, epilepsy\), Adamas](#)
Highest Status: Suspended
Last Change Date: 23-Mar-2020
Adamas Pharmaceuticals was developing ADS-4101, an extended-release formulation of the CRMP-2 and sodium channel slow inactivation modulator for the potential treatment of epilepsy including partial onset seizures [1726996], [1730656], [1889546].
- Drugs (4)**: [lacosamide \(oral controlled release, epilepsy\), SK Chemicals](#)
Highest Status: No Development Reported
Last Change Date: 27-Sep-2019
SK Chemicals was investigating SID-1601, a controlled-release formulation of the collapsin response mediator protein 2 (CRMP-2) and sodium channel slow inactivation modulator **lacosamide**, presumably for the potential once-daily oral treatment of partial onset seizures [1957839].
- Literature (942)**: [lacosamide \(extended release\), BioPharmartis/ Hyundai](#)
Highest Status: No Development Reported
Last Change Date: 20-Jul-2017
Hyundai Pharmaceutical, together with its affiliate BioPharmartis, was developing BPDO-1602 (formerly BPS-015), a controlled (sustained) release tablet of **lacosamide** for the potential treatment of epilepsy [1671541], [1746194].

A callout box highlights the "Show hit fields" button in the toolbar, stating: "Hit highlighting helps you find your keyword quicker in List View, available from the tool bar top right."

Example 2: *Full Text* search “lacosamide” retrieves 13 results, including other drugs that mention lacosamide in their drug profile or make reference to it as a competitor or related product.

13 results found for full text search for the search term 'lacosamide'

Results Per page: 10 Sort by: Highest Phase Highest to Lowest Order Columns View

cenobamate
 Highest Status: Launched
 Last Change Date: 15-Apr-2021
 SK BioPharmaceuticals (a spin-out of SK Corp) has developed and launched the voltage gated calcium channel (VGCC) inhibitor lacosamide (YKP-3089; XCOPRI) (GABAA) ion channel, and presynaptic GABA release enhancer cenobamate (YKP-3089; XCOPRI) for the treatment of focal onset seizures [615996], [1675508], [2075631], [2220469], [2276499], [2387088], [2399537]. In February 2021, SK BioPharmaceuticals announced that it had entered into a license agreement with SK BioPharmaceuticals to develop and commercialize lacosamide in combination with cenobamate for the treatment of focal onset seizures.
 Development Profile Premarketing: Among patients still on cenobamate (n = 183), patients who came off cenobamate (n = 66) and patients who were seizure-free for > 12 months (n = 62), the percentage of patients taking lacosamide was 43.2, 34.8 and 41.9%; levetiracetam was 35, 36.4 and 41.9%; lamotrigine was 28.4, 25.8 and 27.4%; and zonisamide was 16.4, 10.6 and 22.6%, respectively [2382360].

After clicking 'Show hit fields', you will see more details on the location of your keyword. Click 'Hide hit fields' to go back to summarized view.

Show hit fields Hide hit fields

The *Full Text* option searches your keyword in all fields available in Cortellis, including those that are not indexed by the editorial team, such as titles, profiles, and abstracts. *Full Text* search typically retrieves more results, although some of them may not be as relevant. This type of search is also available for all report types in *Quick Search* and some fields in *Advanced Search*.

Full Text search is recommended when you are interested in non-indexed keyword(s) such as bilirubin, bioterrorism, first filing of patent or a company seeking to outlicense a drug.

Example 3: Use *Full Text* search to find keywords mentioned in deal reports.

Report Type Results Per page: 25 Sort by: Most Recent Event Date Most Recent Order Columns Financial Summary Download View

Show selected only Show hit fields

Broker Research (1271) **Bavarian Nordic to supply IMVAMUNE smallpox vaccine to BARDA**
 Most Recent Event Date: 16-Dec-2020
 Deal Start Date: 30-Nov-2007
 In July 2010, Bavarian Nordic delivered 1 million doses of IMVAMUNE to the US Strategic National Stockpile for the potential use in the event of a smallpox bioterrorism attack in the US.

Clinical Trials (7)

Companies (78)

Conferences (98)

Deals (60) **DTRA to award Ology Bioservices funding to manufacture ATI-1701 for tularemia**
 Most Recent Event Date: 27-Oct-2020
 Deal Start Date: 27-Oct-2020
 ATI-1701, a live attenuated vaccine for the prevention of Francisella tularensis infection, a bioterrorism agent, is being developed and manufactured by Ology Biosciences. Ology Biosciences will manufacture the vaccine candidate under Current Good Manufacturing Practice guidelines and perform a Phase 1 clinical trial in cooperation with Ology Biosciences (see separate October 2020 deal) [2348220], [2348218].

'List view' is available for clinical trials, deals, patents, drugs and other report types.

Example 4: Use *Full Text* search to find references or comments on how a trial was conducted or results found.

Report Type Results Per page: 25 Sort by: Last Change Date Most Recent Order Columns View

Show selected only Show hit fields

Broker Research (3473) **Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC)**

Clinical Trials (52293) **Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC)**
 Phase: Phase 2 Clinical
 Recruitment Status: Not yet recruiting
 Reason for Trial Discontinuation:
 If no cirrhosis: bilirubin should be <= 1.5 x ULN ALT or AST <= 5 x ULN Creatinine or measured or calculated creatinine clearance should be >= 30 ml/min/1.73 m2 for participant with creatinine levels >= 1.5 x institutional upper limit of normal or >= 30 ml/min/1.73 m2 for participant with creatinine levels >= 1.5 x institutional upper limit of normal; AST (SGOT) = aspartate aminotransferase (serum glutamic oxaloacetic transaminase) (SGOT) or eGFR should be calculated per institutional standard Patients must have at least 1 focus of concern on CT scan at baseline and undergo this.

Companies (11)

Conferences (1273)

'List view' allows you to identify the most relevant hits faster from your results page.

Example 5: Use *Full Text* search to find keywords within drug reports.

945 results found for full text search for the search term "'seeking to outlicense" AND 2021'

Results Per page: 25 Sort by: Relevance Order Columns View

AdCOVID
 Highest Status: Phase 1 Clinical
 Last Change Date: 16-Apr-2021
 In February 2020, the company was seeking to outlicense the vaccine for potential partners [2250194].
 Development Profile Additional Information: In March 2021, Altimmune partnered with Summit Biosciences, to manufacture and commercialize AdCOVID for the convenient and cost effective vaccination [2424639].
 Development Profile Preclinical: In March 2021, preclinical data were reported.
 Development Profile Premarketing: In February 2021, the US FDA cleared an IND application to initiate the phase I trial.
 Development Profile Regulatory: In November 2020, commercialization of the vaccine was expected in 2021 [2357382].
 Development Profile Summary: In February 2020, the company was seeking to outlicense the vaccine for potential partners [2250194].

Use speech marks when searching more than one word. Then Cortellis will search for "seeking to outlicense" rather than "seeking AND to AND outlicense".

For more information contact Customer Service at **LS Product Support**